Key facts
- Kamau Therapeutics’s last known valuation is $48.5M (Jun 2025).
- It has raised $31.8M across 1 recorded rounds; the latest was Seed Round ($5.0M) in May 2025.
- Notable investors include Draper Associates, Modi Ventures, NEVA SGR.
- Kamau Therapeutics has filed 1 Form D with the SEC, most recently Jun 2025 ($5.0M sold to 6 investors).
- Status: Privately Held (backing).
Investors
3- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Kamau Therapeutics
Funding rounds
1 roundsAbout Kamau Therapeutics
Operator of a clinical-stage, next-generation gene correction company intended to cure serious and life-threatening diseases. The company develops a new class of therapies to cure a wide range of serious and life-threatening diseases and uses a gene correction approach, called homology-directed repair (HDR), which overcomes prior limitations in specificity, efficiency, and durability of gene editing to offer broad potential for transforming human health outcomes through the delivery of one-time curative cell therapies, enabling medical practitioners to provide quality treatments to their patients.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2023
- Employees
- 9
- Website
- kamautx.com/
- Ownership
- Privately Held (backing)
Kamau Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kamau Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kamau Therapeutics in its N-PORT filings yet. We sweep new filings monthly.